• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬前列腺癌与人前列腺癌变体之间的分子异同

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.

作者信息

Vasilatis Demitria M, Lucchesi Christopher A, Ghosh Paramita M

机构信息

Department of Urologic Surgery, School of Medicine, University of California Davis, Sacramento, CA 95718, USA.

Veterans Affairs (VA)-Northern California Healthcare System, Mather, CA 95655, USA.

出版信息

Biomedicines. 2023 Apr 5;11(4):1100. doi: 10.3390/biomedicines11041100.

DOI:10.3390/biomedicines11041100
PMID:37189720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10136260/
Abstract

Dogs are one of few species that naturally develop prostate cancer (PCa), which clinically resembles aggressive, advanced PCa in humans. Moreover, PCa-tumor samples from dogs are often androgen receptor (AR)-negative and may enrich our understanding of AR-indifferent PCa in humans, a highly lethal subset of PCa for which few treatment modalities are available This narrative review discusses the molecular similarities between dog PCa and specific human-PCa variants, underscoring the possibilities of using the dog as a novel pre-clinical animal model for human PCa, resulting in new therapies and diagnostics that may benefit both species.

摘要

狗是少数能自然发生前列腺癌(PCa)的物种之一,其临床症状与人类侵袭性、晚期PCa相似。此外,狗的PCa肿瘤样本通常为雄激素受体(AR)阴性,这可能有助于我们加深对人类AR不敏感PCa的理解,AR不敏感PCa是PCa中一个高度致命的亚群,目前可用的治疗方式很少。这篇叙述性综述讨论了狗PCa与特定人类PCa变体之间的分子相似性,强调了将狗用作人类PCa新型临床前动物模型的可能性,从而带来可能使两个物种都受益的新疗法和诊断方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b578/10136260/fe62d2be6e1d/biomedicines-11-01100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b578/10136260/fe62d2be6e1d/biomedicines-11-01100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b578/10136260/fe62d2be6e1d/biomedicines-11-01100-g001.jpg

相似文献

1
Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants.犬前列腺癌与人前列腺癌变体之间的分子异同
Biomedicines. 2023 Apr 5;11(4):1100. doi: 10.3390/biomedicines11041100.
2
Comparative pathology of dog and human prostate cancer.犬与人前列腺癌的比较病理学。
Vet Med Sci. 2022 Jan;8(1):110-120. doi: 10.1002/vms3.642. Epub 2021 Oct 10.
3
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.雄激素受体在激素依赖性和去势抵抗性前列腺癌中的作用。
Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13.
4
Role of androgen receptor splice variants in prostate cancer metastasis.雄激素受体剪接变体在前列腺癌转移中的作用。
Asian J Urol. 2016 Oct;3(4):177-184. doi: 10.1016/j.ajur.2016.08.003. Epub 2016 Aug 20.
5
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.原发性前列腺癌中预先存在的去势抵抗性前列腺癌细胞样细胞促进对激素治疗的抵抗。
Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17.
6
Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer.初治雄激素依赖性前列腺癌中雄激素受体(AR)及AR剪接变体(AR-SVs)表达的种族差异
Biomedicines. 2023 Feb 21;11(3):648. doi: 10.3390/biomedicines11030648.
7
Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.在原位VCaP人前列腺癌异种移植模型中,去势诱导瘤内雄激素生物合成及雄激素受体表达上调。
Am J Pathol. 2014 Aug;184(8):2163-73. doi: 10.1016/j.ajpath.2014.04.010. Epub 2014 Jun 17.
8
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.雄激素受体(AR)在前列腺癌中的异质性与治疗抵抗。
Cancer Lett. 2021 Oct 10;518:1-9. doi: 10.1016/j.canlet.2021.06.006. Epub 2021 Jun 10.
9
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression.使用 Malat1 小干扰 RNA 或雄激素受体剪接变体 7 降解增强剂 ASC-J9 进行临床前研究以抑制恩杂鲁胺耐药前列腺癌的进展。
Eur Urol. 2017 Nov;72(5):835-844. doi: 10.1016/j.eururo.2017.04.005. Epub 2017 May 18.
10
Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.雄激素受体依赖性去势抵抗性前列腺癌的综合基因组学研究鉴定出一种由阿片受体 κ1 介导的适应途径。
Commun Biol. 2022 Apr 1;5(1):299. doi: 10.1038/s42003-022-03227-w.

引用本文的文献

1
Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance.犬和人前列腺癌的比较转录组鉴定去势抵抗的介质。
Vet Comp Oncol. 2024 Dec;22(4):629-640. doi: 10.1111/vco.13017. Epub 2024 Oct 7.
2
Alterations in Tumor Aggression Following Androgen Receptor Signaling Restoration in Canine Prostate Cancer Cell Lines.雄激素受体信号恢复后犬前列腺癌细胞系中肿瘤侵袭性的改变。
Int J Mol Sci. 2024 Aug 7;25(16):8628. doi: 10.3390/ijms25168628.
3
Canine on the Couch: The New Canary in the Coal Mine for Environmental Health Research.

本文引用的文献

1
Appraising Animal Models of Prostate Cancer for Translational Research: Future Directions.评估用于转化研究的前列腺癌动物模型:未来方向
Anticancer Res. 2023 Jan;43(1):275-281. doi: 10.21873/anticanres.16160.
2
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.前列腺癌的侵袭性变体:神经内分泌转分化的潜在机制。
J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. doi: 10.1186/s13046-022-02255-y.
3
An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes.
沙发上的犬类:环境健康研究中的新警示信号
Environ Health (Wash). 2024 May 27;2(8):517-529. doi: 10.1021/envhealth.4c00029. eCollection 2024 Aug 16.
基于 RNA-Seq 的犬前列腺癌特征分析及临床相关生物标志物候选基因的优先级排序框架。
Int J Mol Sci. 2021 Oct 25;22(21):11481. doi: 10.3390/ijms222111481.
4
Comparative pathology of dog and human prostate cancer.犬与人前列腺癌的比较病理学。
Vet Med Sci. 2022 Jan;8(1):110-120. doi: 10.1002/vms3.642. Epub 2021 Oct 10.
5
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.雄激素受体(AR)在前列腺癌中的异质性与治疗抵抗。
Cancer Lett. 2021 Oct 10;518:1-9. doi: 10.1016/j.canlet.2021.06.006. Epub 2021 Jun 10.
6
Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.超越雄激素受体:序列、突变体以及在去势抵抗性转移性前列腺癌治疗中的新策略。
Am Soc Clin Oncol Educ Book. 2021 Jun;41:e190-e202. doi: 10.1200/EDBK_321209.
7
Histological and immunohistochemical investigation of canine prostate carcinoma with identification of common intraductal carcinoma component.犬前列腺癌的组织学和免疫组织化学研究,鉴定常见的导管内癌成分。
Vet Comp Oncol. 2022 Mar;20(1):38-49. doi: 10.1111/vco.12704. Epub 2021 May 18.
8
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.雄激素受体依赖性机制介导前列腺癌的耐药性。
Cancers (Basel). 2021 Mar 26;13(7):1534. doi: 10.3390/cancers13071534.
9
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.缺乏 AR 活性的前列腺癌的异质性将需要不同的治疗方法。
Endocr Relat Cancer. 2021 Jul 15;28(8):T51-T66. doi: 10.1530/ERC-21-0002.
10
Clinical considerations for the management of androgen indifferent prostate cancer.雄激素不敏感前列腺癌治疗的临床注意事项。
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):623-637. doi: 10.1038/s41391-021-00332-5. Epub 2021 Feb 10.